Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Slides:

Advertisements

Similar presentations

Long-term non-invasive ventilation in cystic fibrosis — Experience over two decades William G. Flight, Jonathan Shaw, Susan Johnson, A. Kevin Webb, Andrew.

Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan

The prevalence of “risky behaviour” in adults with cystic fibrosis

Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery J. Abbott, J.S. Elborn, A.M. Georgiopoulos,

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

K. Budding, E.A. van de Graaf, T. Hoefnagel, C.E. Hack, H.G. Otten

Megan W. France, Mary E. Dodd, John R. Govan, Catherine J. Doherty, A

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients Luis Pablo Gravina, Carolina Crespo, Hilda.

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis T.O. Hirche, H. Hirche, S. Jungblut,

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population Brandie D. Wagner, Frank J. Accurso,

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited Abaigeal D. Jackson, Leslie Daly,

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

Ghrelin and leptin levels in young adults with cystic fibrosis: Relationship with body fat Charilaos Stylianou, Assimina Galli-Tsinopoulou, George Koliakos,

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Nasal polyposis in lung transplant recipients with cystic fibrosis

Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients Marie-Claire Ishimo, Linda Belson, Sophie Ziai, Emile Levy, Yves.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Ristan M. Greer, Helen M. Buntain, Peter J. Lewindon, Claire E

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Absence of a gender gap in survival

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

H. White, A.M. Morton, D.G. Peckham, S.P. Conway

Presentation transcript:

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb, C. Cardwell, M.M. Tunney, J.S. Elborn Journal of Cystic Fibrosis Volume 13, Issue 1, Pages 63-68 (January 2014) DOI: 10.1016/j.jcf.2013.06.002 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Relationship between IgG and IgA titre for patients (n=67) chronically colonised with P. aeruginosa. IgA and IgG results were log transformed to achieve normal distribution of data. Journal of Cystic Fibrosis 2014 13, 63-68DOI: (10.1016/j.jcf.2013.06.002) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Comparison of (A) serum IgG and (B) serum IgA titre in healthy control subjects (n=118), P. aeruginosa negative CF patients (PA−ve, n=36) and patients chronically colonised with P. aeruginosa (PA+ve, n=67). Mean and (95% CI) values for IgG are: control: 24.29 (21.49–27.09); PA−ve: 35.26 (22.35–48.16); PA+ve: 349.7 (246.2–453.2) and for IgA: control: 12.20 (10.01–14.39); PA−ve: 37.03 (4.12–69.94); PA+ve: 381.2 (−13.74–776.2). Journal of Cystic Fibrosis 2014 13, 63-68DOI: (10.1016/j.jcf.2013.06.002) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Kaplan–Meier plot illustrating survival in two groups defined by the median IgG (110ELISAunits) with patients grouped using a categorical variable above and below 110. Journal of Cystic Fibrosis 2014 13, 63-68DOI: (10.1016/j.jcf.2013.06.002) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions